NIIMBL technology roadmaps propose solutions to critical manufacturing challenges in three key topic areas: Antibody-Drug Conjugates (ADC) and Bispecific Antibodies, Gene Therapies, and Vaccines.
The Institute convened subject matter experts from industry, academic institutions, non-profits, and federal agencies to survey the current landscape and identify areas of opportunity for each of these product classes. The process also included participants focused on workforce development and regulatory considerations.
NIIMBL’s industry roadmap efforts will continue as we address additional topics.
Our industry roadmap efforts will continue as we address additional topics.
We offer a variety of membership options that give you the flexibility to choose your organization’s level of engagement based on technology interests and priorities.